BioForce Nanosciences sees control shift, executive departures
On April 15, 2026, Merle Ferguson, a director and majority shareholder, sold 26,700,000 shares representing 79.65% of outstanding common stock to Nexus…
$400,000,79.65%26.7M
Company
SEC filing news and material events for BIOFORCE NANOSCIENCES HOLDINGS, INC., briefed from primary-source filings.
1 story
On April 15, 2026, Merle Ferguson, a director and majority shareholder, sold 26,700,000 shares representing 79.65% of outstanding common stock to Nexus…